Odanacatib, a cathepsin‐K inhibitor for osteoporosis: a two‐year study in postmenopausal women with low bone density
HG Bone, MR McClung, C Roux… - Journal of Bone and …, 2010 - academic.oup.com
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen.
Odanacatib selectively and reversibly inhibited cathepsin K and rapidly decreased bone …
Odanacatib selectively and reversibly inhibited cathepsin K and rapidly decreased bone …
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three‐year continued therapy and resolution of effect
JA Eisman, HG Bone, DJ Hosking… - Journal of Bone and …, 2011 - academic.oup.com
The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral
density (BMD) and decreased bone‐resorption markers during 2 years of treatment in …
density (BMD) and decreased bone‐resorption markers during 2 years of treatment in …
Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double‐blind, randomized, placebo‐controlled …
SA Stoch, S Zajic, J Stone, DL Miller… - Clinical …, 2009 - Wiley Online Library
Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double‐
blind, randomized, placebo‐controlled phase I studies, postmenopausal female subjects …
blind, randomized, placebo‐controlled phase I studies, postmenopausal female subjects …
[HTML][HTML] Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term …
HG Bone, DW Dempster, JA Eisman… - Osteoporosis …, 2015 - Springer
Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal
osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and …
osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and …
Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women
RD Chapurlat - Therapeutic advances in musculoskeletal …, 2015 - journals.sagepub.com
Odanacatib is a cathepsin K inhibitor developed for the treatment of postmenopausal
osteoporosis. It is a bone resorption inhibitor, but which preserves bone formation to some …
osteoporosis. It is a bone resorption inhibitor, but which preserves bone formation to some …
Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study
B Langdahl, N Binkley, H Bone… - Journal of Bone and …, 2012 - academic.oup.com
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that is highly
expressed by osteoclasts. In this 2‐year, phase 2, dose‐ranging trial, postmenopausal …
expressed by osteoclasts. In this 2‐year, phase 2, dose‐ranging trial, postmenopausal …
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics–results from single oral dose studies …
SA Stoch, S Zajic, JA Stone, DL Miller… - British journal of …, 2013 - Wiley Online Library
Aims To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
odanacatib (ODN), a cathepsin K inhibitor, in humans. Methods Two double‐blind …
odanacatib (ODN), a cathepsin K inhibitor, in humans. Methods Two double‐blind …
[HTML][HTML] Therapeutic inhibition of cathepsin K—reducing bone resorption while maintaining bone formation
LT Duong - BoneKEy reports, 2012 - ncbi.nlm.nih.gov
Osteoporosis is a disease of high bone remodeling with an imbalance of bone resorption
over bone formation, resulting in decreased bone mineral density and deterioration of bone …
over bone formation, resulting in decreased bone mineral density and deterioration of bone …
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension …
MR McClung, ML O'Donoghue… - The lancet Diabetes & …, 2019 - thelancet.com
Background Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining
bone formation. Previous work has shown that odanacatib increases bone mineral density in …
bone formation. Previous work has shown that odanacatib increases bone mineral density in …
Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis
JA Stone, JB McCrea, R Witter, S Zajic… - British journal of …, 2019 - Wiley Online Library
Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and
localized in the lysosomes and resorption lacunae of these cells. CatK is the principal …
localized in the lysosomes and resorption lacunae of these cells. CatK is the principal …
相关搜索
- postmenopausal women bone density
- postmenopausal women odanacatib in the treatment
- postmenopausal women continued therapy
- postmenopausal women resolution of effect
- odanacatib in the treatment continued therapy
- odanacatib for the treatment development history
- bone resorption therapeutic inhibition
- odanacatib for the treatment long term
- postmenopausal osteoporosis development history
- postmenopausal osteoporosis long term
- odanacatib for the treatment postmenopausal osteoporosis